breast cancer – Page 2

Timing the Tactic: SONIA Trial Finds No Survival Advantage for First-Line vs. Second-Line CDK4/6 Inhibition in Advanced Breast Cancer

By MedXY 02/19/2026

The phase 3 SONIA trial demonstrates that initiating CDK4/6 inhibitors in the first-line setting does not improve overall survival compared to second-line use in HR-positive, ERBB2-negative advanced breast cancer, while significantly increasing toxicity and treatment duration.

Cardiology news Oncology

Environmental Cardiotoxicity: PM2.5 and Ozone Exposure Double the Risk of Cardiac Dysfunction in Breast Cancer Patients

By MedXY 02/09/2026

A prospective study reveals that PM2.5 and ozone exposure significantly exacerbate cardiac dysfunction and adverse remodeling in breast cancer patients receiving anthracyclines or trastuzumab, doubling the risk of clinical LVEF decline.

news Oncology Public Health

Mammography Screening and Mortality: A 40-Year European Population-Based Evaluation Shows Shift to Early-Stage Detection

By MedXY 01/28/2026

A massive 21-country study confirms that mammography screening has significantly shifted breast cancer detection toward earlier stages, contributing to a substantial decline in mortality across Europe, though treatment advances also play a critical role.

news Oncology

Liposomal Irinotecan Offers New Hope for HER2-Negative Breast Cancer Brain Metastases: Insights from the PHENOMENAL Study

By MedXY 01/20/2026

The PHENOMENAL phase 2 study reveals that liposomal irinotecan (nal-IRI) achieves a 22% intracranial objective response rate in patients with HER2-negative breast cancer and brain metastases, addressing a critical unmet need in neuro-oncology despite modest overall survival benefits.

news Oncology

Machine Learning Accurately Predicts Distant Recurrence and Ribociclib Treatment Benefit in HR+/HER2- Early Breast Cancer

By MedXY 01/13/2026

Researchers have developed a machine learning model using real-world and clinical trial data to predict distant recurrence risk and ribociclib's therapeutic effect in HR+/HER2- early breast cancer, offering a potential tool for personalized adjuvant treatment decisions.

news Oncology

T-DXd Combinations Redefine Therapeutic Boundaries in HER2-Low Metastatic Breast Cancer: Key Findings from DESTINY-Breast08

By MedXY 01/13/2026

The DESTINY-Breast08 phase 1b study demonstrates that trastuzumab deruxtecan (T-DXd) combined with chemotherapy, AKT inhibitors, or endocrine therapy is manageable and clinically active in HER2-low metastatic breast cancer, offering new pathways for treatment intensification.

news Oncology

Palbociclib, Trastuzumab, and Endocrine Therapy Significantly Extend Progression-Free Survival in PAM50 Luminal HER2-Positive Advanced Breast Cancer: Results from the SOLTI-1303 PATRICIA Trial

By MedXY 01/12/2026

The Phase II SOLTI-1303 PATRICIA trial (Cohort C) demonstrates that a triplet regimen of palbociclib, trastuzumab, and endocrine therapy significantly improves progression-free survival compared to physician's choice treatments in pretreated patients with HER2-positive, PAM50 luminal subtype advanced breast cancer.

news Oncology

Neoadjuvant Abemaciclib plus Letrozole: A Potential Chemotherapy-Sparing Strategy in Select HR+/HER2- Breast Cancers?

By MedXY 01/11/2026

The CARABELA trial suggests that while neoadjuvant abemaciclib plus letrozole did not meet the threshold for similarity to chemotherapy in highly proliferative HR+/HER2- breast cancer, it remains a viable alternative for patients with lower genomic risk or moderate proliferation indices.

news Oncology

Genomic Evolution of Breast Cancer: How Acquired Gene Fusions Drive Metastatic Progression and Treatment Resistance

By MedXY 01/11/2026

A multi-omics analysis from the AURORA program reveals that metastatic breast cancer carries a significantly higher burden of gene fusions than primary tumors. Acquired fusions, particularly involving ESR1, are linked to genomic instability and poor clinical outcomes.

news Oncology

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

By MedXY 01/09/2026

Explore the Phase 3 TROPION-Breast01 study results, detailing how the antibody-drug conjugate datopotamab deruxtecan offers a superior alternative to standard chemotherapy in advanced HR+/HER2- breast cancer through improved progression-free survival and a manageable safety profile.

news Oncology

Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer

By MedXY 01/09/2026

The Phase II TRADE trial demonstrates that a stepwise dose escalation of abemaciclib significantly improves drug tolerability and reduces early discontinuation rates in patients with high-risk HR-positive, HER2-negative early breast cancer compared to standard initiation protocols.

news Oncology Pathology & Lab Medicine

Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer

By MedXY 01/09/2026

This systematic review and network meta-analysis of 20 randomized trials demonstrate that molecular profiling for ESR1 and PI3K-AKT-PTEN alterations is essential for optimizing endocrine-based strategies after CDK4/6 inhibitor progression, identifying superior combination regimens for specific genomic subgroups.

news Oncology Public Health

High Ultra-Processed Food Consumption Linked to Increased Mortality Among Black Breast Cancer Survivors

By MedXY 01/08/2026

A longitudinal study of 1,733 Black breast cancer survivors reveals that high intake of ultra-processed foods significantly increases both breast cancer-specific and all-cause mortality, highlighting a critical modifiable risk factor for addressing racial disparities in cancer outcomes.

Hematology-Oncology news Oncology

Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial

By MedXY 01/08/2026

The Phase 2b PIONEER trial reveals that adding megestrol to letrozole significantly reduces tumor proliferation in early-stage ER+ breast cancer. By reprogramming estrogen receptor activity, this combination offers a dual benefit of enhanced antitumor efficacy and potential improvement in treatment adherence through hot flash mitigation.

news Oncology

Rethinking the Standard: Is a Chemotherapy-Free Future Possible for HER2-Enriched Breast Cancer?

By MedXY 01/08/2026

The WSG-KEYRICHED-1 trial investigates a chemotherapy-free regimen for HER2-enriched early breast cancer, showing that 47% of patients achieved a pathological complete response using only immunotherapy and dual HER2 blockade.

General Surgery news Oncology

Tailoring Axillary Surgery: Omitting Dissection for Residual Micrometastases After Neoadjuvant Chemotherapy

By MedXY 01/05/2026

The OPBC-07/microNAC study suggests that axillary lymph node dissection can be safely omitted in many breast cancer patients with residual micrometastases post-neoadjuvant chemotherapy, provided nodal radiotherapy is used, though triple-negative disease warrants caution.

Neurology news Oncology

Chemoendocrine Therapy Linked to Greater Cognitive Decline in Breast Cancer Patients, Regardless of Menopausal Status

By MedXY 12/17/2025

A secondary analysis of the RxPONDER trial finds chemoendocrine therapy causes more lasting cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women.

news Oncology

Broad Genetic Testing Reveals Hidden Breast Cancer Risk in Women Without Family History

By MedXY 12/16/2025

The WISDOM trial found that 3.1% of women without breast cancer carried pathogenic variants in key susceptibility genes, many outside existing testing guidelines.

news Oncology Public Health

High, Persistent Breast Cancer Mortality in Sub‑Saharan Africa: 7‑Year ABC‑DO Cohort Reveals Major Survival Gaps and Actionable Targets

By MedXY 11/25/2025

A 7‑year follow-up of 2,153 women in the ABC‑DO cohort shows poor breast cancer survival in much of sub‑Saharan Africa, with 5‑year crude survival 40% and marked between-country and racial disparities; reaching WHO stage downstaging targets and improving treatment access could cut deaths by about a third.

news Oncology Radiology

Preoperative Single‑Fraction Ablative Radiotherapy for Early HR+ Breast Cancer: Low Toxicity, High Pathologic Responses with Delayed Surgery

By MedXY 11/19/2025

A phase 1 trial reports tolerable single‑fraction preoperative stereotactic partial‑breast irradiation (30–38 Gy) with low toxicity, preserved cosmesis, and high pathologic complete response rates when surgery was delayed beyond ~9 months on endocrine therapy.